[S01GX11, alcaftadine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Alcaftadine.]
[P02BB01, trichlorfon, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The serum concentration of Antipyrine can be increased when it is combined with Fluoxetine.]
[B01AD01, streptokinase, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Streptokinase.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Fluoxetine can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Fluoxetine can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Fluoxetine can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Fluoxetine can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Sulindac.]
[N05AL01, sulpiride, Sulpiride may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Azapropazone.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Fluoxetine.]
[L02BA01, tamoxifen, The serum concentration of Tamoxifen can be increased when it is combined with Fluoxetine.]
[N05CD07, temazepam, The serum concentration of Temazepam can be increased when it is combined with Fluoxetine.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Fluoxetine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Fluoxetine.]
[N07XX06, tetrabenazine, The serum concentration of Tetrabenazine can be increased when it is combined with Fluoxetine.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AE05, lurasidone, The risk or severity of serotonin syndrome can be increased when Lurasidone is combined with Fluoxetine.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N04BC07, apomorphine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Fluoxetine.]
[L04AX02, thalidomide, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Fluoxetine.]
[R03DA04, theophylline, The serum concentration of Theophylline can be increased when it is combined with Fluoxetine.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be decreased when combined with Fluoxetine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Fluoxetine.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Fluoxetine.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C01BB04, aprindine, The serum concentration of Aprindine can be increased when it is combined with Fluoxetine.]
[B02AB01, aprotinin, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Aprotinin.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Fluoxetine.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Fluoxetine.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[B01AC05, ticlopidine, The serum concentration of Ticlopidine can be increased when it is combined with Fluoxetine.]
[N02AX01, tilidine, The risk or severity of serotonin syndrome can be increased when Tilidine is combined with Fluoxetine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Fluoxetine.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Tolmetin.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Fluoxetine.]
[C01DX11, trapidil, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Trapidil.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluoxetine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Fluoxetine.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Fluoxetine.]
[N05CD05, triazolam, The serum concentration of Triazolam can be increased when it is combined with Fluoxetine.]
[C03AA06, trichlormethiazide, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Trichlormethiazide.]
[A03AB12, mepenzolate, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N04AA01, trihexyphenidyl, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Trimebutine.]
[S01ED04, metipranolol, The serum concentration of Metipranolol can be increased when it is combined with Fluoxetine.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Fluoxetine.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Fluoxetine.]
[R06AC04, tripelennamine, The metabolism of Fluoxetine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A03BB01, butylscopolamine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The serum concentration of Vilazodone can be increased when it is combined with Fluoxetine.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Tropicamide.]
[N06AX02, tryptophan, The risk or severity of serotonin syndrome can be increased when Tryptophan is combined with Fluoxetine.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Fluoxetine.]
[S01AA05, tyrothricin, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Vandetanib.]
[L02BX03, abiraterone, The serum concentration of Fluoxetine can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Linagliptin.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Urokinase.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[B01AF01, rivaroxaban, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Fluoxetine.]
[N06AX09, viloxazine, Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Fluoxetine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Fluoxetine.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Fluoxetine.]
[B01AA03, warfarin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Warfarin.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Fluoxetine.]
[N05AF05, zuclopenthixol, The serum concentration of Zuclopenthixol can be increased when it is combined with Fluoxetine.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01EC01, vemurafenib, The serum concentration of Fluoxetine can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Fluoxetine.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Fluoxetine can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Fluoxetine.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Fluoxetine.]
[N02BA01, aspirin, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Fluoxetine.]
[G04BD07, tolterodine, The serum concentration of Tolterodine can be increased when it is combined with Fluoxetine.]
[C07AB03, atenolol, The serum concentration of Atenolol can be increased when it is combined with Fluoxetine.]
[L03AB11, peginterferon alfa-2a, The metabolism of Fluoxetine can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Voriconazole.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Atropine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Fluoxetine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Fluoxetine.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Fluoxetine.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Fluoxetine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A08AA11, lorcaserin, The serum concentration of Lorcaserin can be increased when it is combined with Fluoxetine.]
[G04BD12, mirabegron, The serum concentration of Fluoxetine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Fluoxetine can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, The serum concentration of Fluoxetine can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fluoxetine.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Fluoxetine.]
[L04AA31, teriflunomide, The serum concentration of Fluoxetine can be decreased when it is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Defibrotide.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Fluoxetine.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Fluoxetine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N04BD02, rasagiline, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Fluoxetine.]
[A03FA09, mosapride, The risk or severity of serotonin syndrome can be increased when Mosapride is combined with Fluoxetine.]
[N06DA02, donepezil, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The serum concentration of Darifenacin can be increased when it is combined with Fluoxetine.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Fluoxetine.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Sildenafil can be increased when it is combined with Fluoxetine.]
[L01EA05, ponatinib, The serum concentration of Ponatinib can be increased when it is combined with Fluoxetine.]
[B01AF02, apixaban, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Fluoxetine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Bencyclane.]
[A10BH04, alogliptin, The serum concentration of Alogliptin can be increased when it is combined with Fluoxetine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Fluoxetine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Fluoxetine.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Benorilate.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Fluoxetine can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Fluoxetine.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Fluoxetine.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin detemir.]
[R02AD01, benzocaine, The serum concentration of Benzocaine can be increased when it is combined with Fluoxetine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Pramlintide.]
[M01AH01, celecoxib, The risk or severity of bleeding can be increased when Celecoxib is combined with Fluoxetine.]
[N02CC02, naratriptan, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Fluoxetine.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Fluoxetine.]
[N04AC01, benztropine, The serum concentration of Benzatropine can be increased when it is combined with Fluoxetine.]
[L01EC02, dabrafenib, The serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The serum concentration of Benzyl alcohol can be increased when it is combined with Fluoxetine.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fluoxetine.]
[N06AX28, levomilnacipran, The serum concentration of Levomilnacipran can be increased when it is combined with Fluoxetine.]
[C08EA02, bepridil, The serum concentration of Bepridil can be increased when it is combined with Fluoxetine.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Lixisenatide.]
[L01EL01, ibrutinib, The serum concentration of Ibrutinib can be increased when it is combined with Fluoxetine.]
[N06AX26, vortioxetine, The serum concentration of Vortioxetine can be increased when it is combined with Fluoxetine.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[D01AC18, luliconazole, The serum concentration of Fluoxetine can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Fluoxetine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10BK01, dapagliflozin, The serum concentration of Dapagliflozin can be increased when it is combined with Fluoxetine.]
[C07AB04, acebutolol, The serum concentration of Acebutolol can be increased when it is combined with Fluoxetine.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L04AA32, apremilast, The metabolism of Fluoxetine can be increased when combined with Apremilast.]
[A16AA06, betaine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Betaine.]
[S03BA03, betamethasone, The metabolism of Fluoxetine can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be increased when it is combined with Fluoxetine.]
[B01AE03, argatroban, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Argatroban.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Fluoxetine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ceritinib.]
[B01AC26, vorapaxar, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Vorapaxar.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Acenocoumarol.]
[L01XH04, belinostat, The metabolism of Fluoxetine can be increased when combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Fluoxetine.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Olodaterol.]
[D11AA01, glycopyrronium, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Eliglustat can be increased when it is combined with Fluoxetine.]
[J01XA05, oritavancin, The metabolism of Fluoxetine can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[V04CX03, methacholine, Fluoxetine may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Fluoxetine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Dulaglutide.]
[A06AH03, naloxegol, The risk or severity of serotonin syndrome can be increased when Naloxegol is combined with Fluoxetine.]
[N04AA02, biperiden, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The serum concentration of Pirfenidone can be increased when it is combined with Fluoxetine.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Fluoxetine.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Fluoxetine.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Fluoxetine.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Fluoxetine.]
[B01AA01, dicumarol, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Edoxaban.]
[N06AX11, mirtazapine, Fluoxetine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Fluoxetine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Fluoxetine.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Panobinostat.]
[N02BE01, acetaminophen, The serum concentration of Acetaminophen can be increased when it is combined with Fluoxetine.]
[A03AA09, difemerine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ivabradine.]
[J05AP06, asunaprevir, The serum concentration of Asunaprevir can be increased when it is combined with Fluoxetine.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Fluoxetine is combined with Eluxadoline.]
[B01AC25, cangrelor, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Cangrelor.]
[N05AX16, brexpiprazole, The serum concentration of Brexpiprazole can be increased when it is combined with Fluoxetine.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Fluoxetine.]
[A04AD14, rolapitant, The metabolism of Fluoxetine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of serotonin syndrome can be increased when Flibanserin is combined with Fluoxetine.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Fluoxetine.]
[N05AX15, cariprazine, The risk or severity of serotonin syndrome can be increased when Cariprazine is combined with Fluoxetine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin degludec.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A02BC03, lansoprazole, The metabolism of Fluoxetine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The serum concentration of Trabectedin can be increased when it is combined with Fluoxetine.]
[J02AC05, isavuconazole, The metabolism of Fluoxetine can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Fluoxetine can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Fluoxetine.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Fluoxetine.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Fluoxetine.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Fluoxetine.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Acetohexamide.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Alfuzosin.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Fluoxetine.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Alminoprofen.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Fluoxetine.]
[N05BA08, bromazepam, The serum concentration of Bromazepam can be increased when it is combined with Fluoxetine.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06AA19, amineptin, The serum concentration of Amineptine can be increased when it is combined with Fluoxetine.]
[C08CA01, amlodipine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Amlodipine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Fluoxetine.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A05AA04, obeticholic acid, The metabolism of Fluoxetine can be decreased when combined with Obeticholic acid.]
[S01ED03, levobunolol, The serum concentration of Levobunolol can be increased when it is combined with Fluoxetine.]
[N01BB01, bupivacaine, The serum concentration of Bupivacaine can be increased when it is combined with Fluoxetine.]
[C07AA19, bupranolol, The serum concentration of Bupranolol can be increased when it is combined with Fluoxetine.]
[N07BC01, buprenorphine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Buserelin.]
[N05BE01, buspirone, The serum concentration of Buspirone can be increased when it is combined with Fluoxetine.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Fluoxetine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Fluoxetine.]
[N02AF01, butorphanol, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Fluoxetine.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Azatadine.]
[S01GX07, azelastine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The serum concentration of Rucaparib can be increased when it is combined with Fluoxetine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Azithromycin.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Fluoxetine.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Bambuterol.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Fluoxetine.]
[N07XX16, deutetrabenazine, The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Fluoxetine.]
[N02BF02, pregabalin, The therapeutic efficacy of Fluoxetine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06BC01, caffeine, The metabolism of Fluoxetine can be decreased when combined with Caffeine.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Benfluorex.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Fluoxetine.]
[J05AE09, tipranavir, The serum concentration of Tipranavir can be increased when it is combined with Fluoxetine.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Fluoxetine.]
[N07XX13, valbenazine, The serum concentration of Valbenazine can be increased when it is combined with Fluoxetine.]
[L04AB02, infliximab, The metabolism of Fluoxetine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Fluoxetine.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Fluoxetine.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Fluoxetine.]
[N04BD03, safinamide, The risk or severity of serotonin syndrome can be increased when Safinamide is combined with Fluoxetine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Delafloxacin.]
[B01AF04, betrixaban, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Betrixaban.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Fluoxetine.]
[L01XX59, enasidenib, The serum concentration of Enasidenib can be increased when it is combined with Fluoxetine.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Fluoxetine.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Fluoxetine.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Fluoxetine.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Fluoxetine.]
[J05AG03, efavirenz, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C07AA17, bopindolol, The serum concentration of Bopindolol can be increased when it is combined with Fluoxetine.]
[N04AA11, bornaprine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CD09, brotizolam, The serum concentration of Brotizolam can be increased when it is combined with Fluoxetine.]
[C04AX20, buflomedil, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Fluoxetine.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J05AX18, letermovir, The serum concentration of Letermovir can be increased when it is combined with Fluoxetine.]
[N06AA15, butriptyline, The serum concentration of Butriptyline can be increased when it is combined with Fluoxetine.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Semaglutide.]
[N01BX04, capsaicin, The metabolism of Fluoxetine can be increased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Ertugliflozin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Fluoxetine can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Carbamazepine can be increased when it is combined with Fluoxetine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Fluoxetine.]
[A03AA03, camylofine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Fluoxetine.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L03AB06, interferon alfa-n1, The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be increased when it is combined with Fluoxetine.]
[N03AX24, cannabidiol, The risk or severity of serotonin syndrome can be increased when Cannabidiol is combined with Fluoxetine.]
[B02BX08, avatrombopag, The metabolism of Fluoxetine can be increased when combined with Avatrombopag.]
[L01EC03, encorafenib, The serum concentration of Encorafenib can be increased when it is combined with Fluoxetine.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Fluoxetine.]
[C07AB08, celiprolol, The serum concentration of Celiprolol can be increased when it is combined with Fluoxetine.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Fluoxetine.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ivosidenib.]
[P01BA07, tafenoquine, The serum concentration of Tafenoquine can be increased when it is combined with Fluoxetine.]
[N03AX17, stiripentol, Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J05AX24, tecovirimat, The metabolism of Fluoxetine can be decreased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Fluoxetine.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Fluoxetine.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Carbutamide.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R06AA06, chlorphenoxamine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Fluoxetine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Inotersen.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluoxetine.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Fluoxetine.]
[L04AA39, emapalumab, The metabolism of Fluoxetine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Carmustine can be decreased when combined with Fluoxetine.]
[L01EX13, gilteritinib, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Amifampridine.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Fluoxetine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Cibenzoline.]
[B01AX07, caplacizumab, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Caplacizumab.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Fluoxetine.]
[A03FA08, cinitapride, The risk or severity of serotonin syndrome can be increased when Cinitapride is combined with Fluoxetine.]
[S01ED05, carteolol, The serum concentration of Carteolol can be increased when it is combined with Fluoxetine.]
[P02BX04, triclabendazole, The metabolism of Fluoxetine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Esketamine.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Clarithromycin.]
[N06BA14, solriamfetol, Solriamfetol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Fluoxetine.]
[N05BA09, clobazam, The serum concentration of Clobazam can be increased when it is combined with Fluoxetine.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Fluoxetine.]
[N05BA22, cloxazolam, The serum concentration of Cloxazolam can be increased when it is combined with Fluoxetine.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Ubidecarenone.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Fluoxetine.]
[L04AB01, etanercept, The metabolism of Fluoxetine can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Fluoxetine can be decreased when it is combined with Alpelisib.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Fluoxetine.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Fluoxetine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Fluoxetine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Pitolisant can be increased when it is combined with Fluoxetine.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Fluoxetine.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Fluoxetine.]
[N04CX01, istradefylline, The serum concentration of Istradefylline can be increased when it is combined with Fluoxetine.]
[G04BE04, yohimbine, The serum concentration of Yohimbine can be increased when it is combined with Fluoxetine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Fluoxetine.]
[S01EX02, dapiprazole, Dapiprazole may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Fluoxetine.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Fluoxetine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Fluoxetine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Fluoxetine.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Fluoxetine.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Fluoxetine.]
[N03AX25, cenobamate, The serum concentration of Fluoxetine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Fluoxetine can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Fluoxetine.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R06AB02, dexchlorpheniramine, The serum concentration of Dexchlorpheniramine can be increased when it is combined with Fluoxetine.]
[N02AX03, dezocine, The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Fluoxetine.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Fluoxetine.]
[N05CM21, lemborexant, The serum concentration of Fluoxetine can be decreased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Fluoxetine.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M01AX21, diacetylrhein, The metabolism of Fluoxetine can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Fluoxetine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of Amprenavir can be increased when it is combined with Fluoxetine.]
[N02CC07, frovatriptan, The risk or severity of serotonin syndrome can be increased when Frovatriptan is combined with Fluoxetine.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Fluoxetine.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02AA08, dihydrocodeine, The serum concentration of Dihydrocodeine can be increased when it is combined with Fluoxetine.]
[N02CC06, eletriptan, The serum concentration of Eletriptan can be increased when it is combined with Fluoxetine.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be decreased when combined with Fluoxetine.]
[C08CA16, clevidipine, The serum concentration of Clevidipine can be increased when it is combined with Fluoxetine.]
[C01BD07, dronedarone, Fluoxetine may increase the QTc-prolonging activities of Dronedarone.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[S03AA08, chloramphenicol, The metabolism of Fluoxetine can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, The serum concentration of Chlordiazepoxide can be increased when it is combined with Fluoxetine.]
[A03AA08, dihexyverine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Fluoxetine can be decreased when combined with Capmatinib.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Fluoxetine.]
[G04BD09, trospium, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ebastine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Fluoxetine.]
[N05CD14, remimazolam, The serum concentration of Remimazolam can be increased when it is combined with Fluoxetine.]
[L04AC19, satralizumab, The serum concentration of Fluoxetine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Fluoxetine is combined with Oliceridine.]
[P01BA01, chloroquine, The serum concentration of Chloroquine can be increased when it is combined with Fluoxetine.]
[L01EX23, pralsetinib, The metabolism of Fluoxetine can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Chlorothiazide.]
[D01AE07, chlorphenesin, Chlorphenesin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R06AB04, chlorpheniramine, The serum concentration of Chlorpheniramine can be increased when it is combined with Fluoxetine.]
[N05AA01, chlorpromazine, The serum concentration of Chlorpromazine can be increased when it is combined with Fluoxetine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C03BA04, chlorthalidone, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Chlorthalidone.]
[M03BB03, chlorzoxazone, The serum concentration of Chlorzoxazone can be increased when it is combined with Fluoxetine.]
[A11CC05, cholecalciferol, The metabolism of Fluoxetine can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Ethenzamide.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05BA18, ethyl loflazepate, The serum concentration of Ethyl loflazepate can be increased when it is combined with Fluoxetine.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Fluoxetine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Fluoxetine.]
[P03AX07, abametapir, The serum concentration of Fluoxetine can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Fluoxetine can be decreased when combined with Tepotinib.]
[V03AF12, trilaciclib, The metabolism of Fluoxetine can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Fenbufen.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Fluoxetine.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Flumequine.]
[R03CC15, formoterol, The serum concentration of Formoterol can be increased when it is combined with Fluoxetine.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Fluoxetine.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluoxetine.]
[A02BA01, cimetidine, The metabolism of Fluoxetine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N07CA02, cinnarizine, The serum concentration of Cinnarizine can be increased when it is combined with Fluoxetine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Cinoxacin.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Fluoxetine.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, The serum concentration of Citalopram can be increased when it is combined with Fluoxetine.]
[H01AC07, somapacitan, The metabolism of Fluoxetine can be decreased when combined with Somapacitan.]
[P01CA03, fexinidazole, The serum concentration of Fexinidazole can be increased when it is combined with Fluoxetine.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Fluoxetine.]
[H01AC09, lonapegsomatropin, The metabolism of Fluoxetine can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Fluoxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Gliquidone.]
[N06AX25, St. John's wort extract, The risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with Fluoxetine.]
[L01EA06, asciminib, The metabolism of Fluoxetine can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Fluoxetine.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Fluoxetine.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Tenecteplase.]
[B06AX04, mitapivat, The metabolism of Fluoxetine can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Pacritinib.]
[N06AA04, clomipramine, The serum concentration of Clomipramine can be increased when it is combined with Fluoxetine.]
[N03AE01, clonazepam, The serum concentration of Clonazepam can be increased when it is combined with Fluoxetine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Fluoxetine.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Fluoxetine.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Tirzepatide.]
[A02BC08, vonoprazan, The metabolism of Fluoxetine can be decreased when combined with Vonoprazan.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05BA21, clotiazepam, The serum concentration of Clotiazepam can be increased when it is combined with Fluoxetine.]
[A04AA01, ondansetron, The serum concentration of Ondansetron can be increased when it is combined with Fluoxetine.]
[A04AA02, granisetron, The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Fluoxetine.]
[L01XX77, adagrasib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Adagrasib.]
[N05AH02, clozapine, The serum concentration of Clozapine can be increased when it is combined with Fluoxetine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Sotagliflozin.]
[N05BA13, halazepam, The serum concentration of Halazepam can be increased when it is combined with Fluoxetine.]
[H01AC08, somatrogon, The metabolism of Fluoxetine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of serotonin syndrome can be increased when Cocaine is combined with Fluoxetine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Fluoxetine.]
[L04AC21, bimekizumab, The metabolism of Fluoxetine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Proquazone.]
[R05DA04, codeine, The serum concentration of Codeine can be increased when it is combined with Fluoxetine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A03AB10, hexocyclium, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Homatropine.]
[A03BB06, homatropine methylbromide, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The serum concentration of Fluoxetine can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10BX03, nateglinide, The serum concentration of Nateglinide can be increased when it is combined with Fluoxetine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin glargine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Telithromycin.]
[R03BA08, ciclesonide, The serum concentration of Ciclesonide can be increased when it is combined with Fluoxetine.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Indobufen.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Valdecoxib.]
[H01AX01, pegvisomant, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Pegvisomant.]
[N02CC05, almotriptan, The serum concentration of Almotriptan can be increased when it is combined with Fluoxetine.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Bemiparin.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Fluoxetine.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Emedastine.]
[N05BA10, ketazolam, The serum concentration of Ketazolam can be increased when it is combined with Fluoxetine.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Imatinib can be increased when it is combined with Fluoxetine.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Fluoxetine.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Fluoxetine.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N07BC04, lofexidine, The therapeutic efficacy of Fluoxetine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Lonazolac.]
[R06AX13, loratadine, Fluoxetine may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, The serum concentration of Lormetazepam can be increased when it is combined with Fluoxetine.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Loxoprofen.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Fluoxetine.]
[C08CA11, manidipine, The metabolism of Fluoxetine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C07AA14, mepindolol, The serum concentration of Mepindolol can be increased when it is combined with Fluoxetine.]
[R06AD07, mequitazine, The serum concentration of Mequitazine can be increased when it is combined with Fluoxetine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Adenosine.]
[N04AA03, methixene, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Methoxyphenamine is combined with Fluoxetine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C03AA07, cyclopenthiazide, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Miglitol.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclopentolate.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.]
[N06AX07, minaprine, The risk or severity of serotonin syndrome can be increased when Minaprine is combined with Fluoxetine.]
[S01XA18, cyclosporine, The metabolism of Fluoxetine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of serotonin syndrome can be increased when Moclobemide is combined with Fluoxetine.]
[N06BA07, modafinil, The metabolism of Fluoxetine can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Moexipril.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Fluoxetine.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Fluoxetine.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Fluoxetine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Vardenafil.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Etoricoxib.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Fluoxetine.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Fluoxetine.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C02CC04, debrisoquin, The serum concentration of Debrisoquine can be increased when it is combined with Fluoxetine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Nabumetone.]
[N05BA16, nordazepam, The serum concentration of Nordazepam can be increased when it is combined with Fluoxetine.]
[C07AB12, nebivolol, The serum concentration of Nebivolol can be increased when it is combined with Fluoxetine.]
[N06AX06, nefazodone, The serum concentration of Nefazodone can be increased when it is combined with Fluoxetine.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Fluoxetine.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Fluoxetine.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R05DA06, normethadone, The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Fluoxetine.]
[B01AX05, fondaparinux, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Escitalopram.]
[G04BD08, solifenacin, The serum concentration of Solifenacin can be increased when it is combined with Fluoxetine.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Olsalazine.]
[N06AA01, desipramine, The serum concentration of Desipramine can be increased when it is combined with Fluoxetine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Desmopressin.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[S03BA01, dexamethasone, The metabolism of Fluoxetine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N04AA08, dexetimide, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The serum concentration of Dexfenfluramine can be increased when it is combined with Fluoxetine.]
[A03AA01, oxyphencyclimine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Fluoxetine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The serum concentration of Gefitinib can be increased when it is combined with Fluoxetine.]
[N06BA02, dextroamphetamine, The serum concentration of Amphetamine can be increased when it is combined with Fluoxetine.]
[R05DA09, dextromethorphan, The serum concentration of Dextromethorphan can be increased when it is combined with Fluoxetine.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02AC01, dextromoramide, The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Fluoxetine.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Fluoxetine.]
[N06AB05, paroxetine, The serum concentration of Paroxetine can be increased when it is combined with Fluoxetine.]
[B01AC04, clopidogrel, The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluoxetine resulting in a loss in efficacy.]
[N07BC06, heroin, Diamorphine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Fluoxetine.]
[N05BA01, diazepam, The serum concentration of Diazepam can be increased when it is combined with Fluoxetine.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06AA08, dibenzepin, The serum concentration of Dibenzepin can be increased when it is combined with Fluoxetine.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Foscarnet.]
[A03AA07, dicyclomine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of serotonin syndrome can be increased when Pipamperone is combined with Fluoxetine.]
[A03AB14, pipenzolate, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Fluoxetine.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be increased when it is combined with Fluoxetine.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, The risk or severity of serotonin syndrome can be increased when Diethylpropion is combined with Fluoxetine.]
[L02AA01, diethylstilbestrol, The metabolism of Fluoxetine can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Isradipine.]
[A03AB11, poldine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Digoxin.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Fluoxetine.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Fluoxetine.]
[N02CA01, dihydroergotamine, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Fluoxetine.]
[N02AA03, hydromorphone, The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Fluoxetine.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Treprostinil.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Fluoxetine.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C08DB01, diltiazem, The serum concentration of Diltiazem can be increased when it is combined with Fluoxetine.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R06AB03, dimethindene, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Fluoxetine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Fluoxetine.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Fluoxetine can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, Proparacaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Fluoxetine.]
[R06AA02, diphenhydramine, The serum concentration of Diphenhydramine can be increased when it is combined with Fluoxetine.]
[A07DA01, diphenoxylate, The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Fluoxetine.]
[N05CD10, quazepam, The serum concentration of Quazepam can be increased when it is combined with Fluoxetine.]
[B01AC07, dipyridamole, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of serotonin syndrome can be increased when Dexmethylphenidate is combined with Fluoxetine.]
[B01AD10, drotrecogin alfa, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The serum concentration of Quinupramine can be increased when it is combined with Fluoxetine.]
[A03FA02, cisapride, The risk or severity of serotonin syndrome can be increased when Cisapride is combined with Fluoxetine.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Fluoxetine.]
[N05AL04, remoxipride, The serum concentration of Remoxipride can be increased when it is combined with Fluoxetine.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Fluoxetine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Fluoxetine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AX08, risperidone, The serum concentration of Risperidone can be increased when it is combined with Fluoxetine.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sunitinib.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Fluoxetine.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Fluoxetine.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Ketorolac.]
[C01EB18, ranolazine, The serum concentration of Fluoxetine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Fluoxetine.]
[A03FA03, domperidone, The serum concentration of Domperidone can be increased when it is combined with Fluoxetine.]
[N06AA16, dothiepin, The serum concentration of Dosulepin can be increased when it is combined with Fluoxetine.]
[N06AA12, doxepin, The serum concentration of Doxepin can be increased when it is combined with Fluoxetine.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Fluoxetine.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Fluoxetine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06AB06, sertraline, The serum concentration of Sertraline can be increased when it is combined with Fluoxetine.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A08AA10, sibutramine, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Fluoxetine.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be increased when it is combined with Fluoxetine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Fluoxetine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Fluoxetine.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Fluoxetine.]
[V04CX07, edrophonium, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Fluoxetine.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Fluoxetine can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Terodiline.]
[C07AA16, tertatolol, The serum concentration of Tertatolol can be increased when it is combined with Fluoxetine.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G04BD01, emepronium, Emepronium may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06AX14, tianeptine, The serum concentration of Tianeptine can be increased when it is combined with Fluoxetine.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of serotonin syndrome can be increased when Toloxatone is combined with Fluoxetine.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Fluoxetine.]
[N03AX11, topiramate, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Toremifene.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Fluoxetine.]
[N05CD11, triazulenone, The serum concentration of Loprazolam can be increased when it is combined with Fluoxetine.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A03AB08, tridihexethyl, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Triflusal.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluoxetine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Triptorelin.]
[N04AA12, tropatepine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Troxerutin.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Enoxacin.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Fluoxetine.]
[S01GX10, epinastine, The serum concentration of Epinastine can be increased when it is combined with Fluoxetine.]
[N06AX16, venlafaxine, The serum concentration of Venlafaxine can be increased when it is combined with Fluoxetine.]
[S01EA01, epinephrine, The metabolism of Fluoxetine can be decreased when combined with Epinephrine.]
[N05CF02, zolpidem, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin glulisine.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AX11, zotepine, The risk or severity of serotonin syndrome can be increased when Zotepine is combined with Fluoxetine.]
[B01AD03, anistreplase, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Anistreplase.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[B01AC11, iloprost, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Iloprost.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G02AB03, ergonovine, The risk or severity of serotonin syndrome can be increased when Ergometrine is combined with Fluoxetine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Fluoxetine.]
[N02CA02, ergotamine, The risk or severity of serotonin syndrome can be increased when Ergotamine is combined with Fluoxetine.]
[N03AG01, valproic acid, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Fluoxetine.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Erythromycin.]
[N05CD04, estazolam, The serum concentration of Estazolam can be increased when it is combined with Fluoxetine.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Fluoxetine.]
[H05BX01, cinacalcet, The metabolism of Fluoxetine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Fluoxetine.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Fluoxetine.]
[J04AK02, ethambutol, The metabolism of Fluoxetine can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The serum concentration of Fluvastatin can be increased when it is combined with Fluoxetine.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Gepefrine is combined with Fluoxetine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Fluoxetine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ibutilide.]
[N04AA05, profenamine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N01BX01, ethyl chloride, Ethyl chloride may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The serum concentration of Ethylmorphine can be increased when it is combined with Fluoxetine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Fluoxetine.]
[N05AE03, sertindole, The serum concentration of Sertindole can be increased when it is combined with Fluoxetine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Tacrolimus.]
[A02BA04, nizatidine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Fleroxacin.]
[R06AX11, astemizole, The serum concentration of Astemizole can be increased when it is combined with Fluoxetine.]
[R06AX12, terfenadine, The serum concentration of Terfenadine can be increased when it is combined with Fluoxetine.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Fluoxetine.]
[N06AB08, fluvoxamine, The serum concentration of Fluvoxamine can be increased when it is combined with Fluoxetine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Fluoxetine.]
[C01BC08, encainide, The serum concentration of Encainide can be increased when it is combined with Fluoxetine.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Leuprolide.]
[B05AA05, dextran, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dextran.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Fluoxetine can be increased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Fendiline.]
[N03AX26, fenfluramine, The serum concentration of Fenfluramine can be increased when it is combined with Fluoxetine.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Fluoxetine.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Salbutamol.]
[B01AD05, plasmin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Fibrinolysin.]
[N07AX03, cevimeline, The serum concentration of Cevimeline can be increased when it is combined with Fluoxetine.]
[G04BD02, flavoxate, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The serum concentration of Flecainide can be increased when it is combined with Fluoxetine.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Fluconazole.]
[N07CA03, flunarizine, The serum concentration of Flunarizine can be increased when it is combined with Fluoxetine.]
[N05CD03, flunitrazepam, The serum concentration of Flunitrazepam can be increased when it is combined with Fluoxetine.]
[N06AA14, melitracen, The serum concentration of Melitracen can be increased when it is combined with Fluoxetine.]
[V03AZ01, ethanol, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Fluoxetine can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Fluorouracil.]
[S01AA13, fusidic acid, The serum concentration of Fusidic acid can be increased when it is combined with Fluoxetine.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Pipemidic acid.]
[N07XX04, sodium oxybate, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Mefenamic acid.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Flupentixol.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CD01, flurazepam, The serum concentration of Flurazepam can be increased when it is combined with Fluoxetine.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of serotonin syndrome can be increased when Fluspirilene is combined with Fluoxetine.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Fluoxetine.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Fluoxetine.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G01AX06, furazolidone, The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Fluoxetine.]
[J05AE10, darunavir, The metabolism of Fluoxetine can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Fluoxetine is combined with Eszopiclone.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06DA04, galantamine, The serum concentration of Galantamine can be increased when it is combined with Fluoxetine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Gallopamil.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06AX08, bifemelane, The risk or severity of serotonin syndrome can be increased when Bifemelane is combined with Fluoxetine.]
[C10AB04, gemfibrozil, The metabolism of Fluoxetine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Dasatinib.]
[N04BC06, cabergoline, The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Fluoxetine.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Fluoxetine.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Fluoxetine.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N01AH02, alfentanil, The risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Fluoxetine.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Fluoxetine.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Fluoxetine.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Glipizide.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Fluoxetine.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Dofetilide.]
[C02CA04, doxazosin, The serum concentration of Doxazosin can be increased when it is combined with Fluoxetine.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluoxetine.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sorafenib.]
[C07AB09, esmolol, The serum concentration of Esmolol can be increased when it is combined with Fluoxetine.]
[B01AA12, fluindione, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Fluindione.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Halofantrine.]
[N05AD01, haloperidol, The metabolism of Haloperidol can be decreased when combined with Fluoxetine.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Histrelin.]
[N05AH04, quetiapine, The serum concentration of Quetiapine can be increased when it is combined with Fluoxetine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin aspart.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Fluoxetine.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Heparin.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Fluoxetine.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Fluoxetine.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Mesalazine.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Fluoxetine.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J05AG01, nevirapine, The serum concentration of Nevirapine can be increased when it is combined with Fluoxetine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Fluoxetine can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Hydroflumethiazide.]
[G04BD06, propiverine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The serum concentration of Hydroxychloroquine can be increased when it is combined with Fluoxetine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Fluoxetine can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Ibuprofen.]
[B05CB02, sodium citrate, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Sodium citrate.]
[L01DB06, idarubicin, The serum concentration of Idarubicin can be increased when it is combined with Fluoxetine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Fluoxetine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Fluoxetine.]
[H01AC02, somatrem, The metabolism of Fluoxetine can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Fluoxetine.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Fluoxetine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Fluoxetine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Terlipressin.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Indomethacin.]
[L03AB04, interferon alfa-2a, The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of serotonin syndrome can be increased when Milnacipran is combined with Fluoxetine.]
[A03AA30, piperidolate, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Sitagliptin.]
[N05BA12, alprazolam, The serum concentration of Alprazolam can be increased when it is combined with Fluoxetine.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Buclizine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Fluoxetine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Anagrelide.]
[C07AA01, alprenolol, The serum concentration of Alprenolol can be increased when it is combined with Fluoxetine.]
[C03BA02, quinethazone, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Quinethazone.]
[L03AB09, interferon alfacon-1, The metabolism of Fluoxetine can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The serum concentration of Ipecac can be increased when it is combined with Fluoxetine.]
[N06AA13, iprindole, The serum concentration of Iprindole can be increased when it is combined with Fluoxetine.]
[N06AF05, iproniazid, The risk or severity of serotonin syndrome can be increased when Iproniazid is combined with Fluoxetine.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Fluoxetine.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06AF01, isocarboxazid, The risk or severity of serotonin syndrome can be increased when Isocarboxazid is combined with Fluoxetine.]
[P01AX06, atovaquone, The metabolism of Fluoxetine can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Fluoxetine.]
[R03CB01, isoproterenol, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Isoprenaline.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Exenatide.]
[B01AE06, bivalirudin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Bivalirudin.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[H01AC01, somatropin, The metabolism of Fluoxetine can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Fluoxetine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C02KD01, ketanserin, The risk or severity of serotonin syndrome can be increased when Ketanserin is combined with Fluoxetine.]
[B01AC22, prasugrel, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Prasugrel.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ketoconazole.]
[N05AH03, olanzapine, The serum concentration of Olanzapine can be increased when it is combined with Fluoxetine.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Ketoprofen.]
[V03AC03, deferasirox, The serum concentration of Fluoxetine can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Fluoxetine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Mizolastine.]
[N04BC09, rotigotine, The serum concentration of Rotigotine can be increased when it is combined with Fluoxetine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Fluoxetine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nalidixic acid.]
[C07AG01, labetalol, The serum concentration of Labetalol can be increased when it is combined with Fluoxetine.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Fluoxetine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Fluoxetine.]
[N07AA30, ambenonium, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fluoxetine.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N04BA01, levodopa, The risk or severity of serotonin syndrome can be increased when Levodopa is combined with Fluoxetine.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be increased when it is combined with Fluoxetine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Fluoxetine can be decreased when combined with Armodafinil.]
[N02CA07, lisuride, The serum concentration of Lisuride can be increased when it is combined with Fluoxetine.]
[N06AA07, lofepramine, The serum concentration of Lofepramine can be increased when it is combined with Fluoxetine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Loperamide.]
[N05BA06, lorazepam, The serum concentration of Lorazepam can be increased when it is combined with Fluoxetine.]
[C10AA02, lovastatin, The metabolism of Fluoxetine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Fluoxetine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Fluoxetine.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Fluoxetine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Fluoxetine.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Fluoxetine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Fluoxetine can be increased when used in combination with Magnesium sulfate.]
[P03AX03, malathion, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Malathion.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nilotinib.]
[N06AA21, maprotiline, The serum concentration of Maprotiline can be increased when it is combined with Fluoxetine.]
[A08AA05, mazindol, The risk or severity of serotonin syndrome can be increased when Mazindol is combined with Fluoxetine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, The serum concentration of Meclizine can be increased when it is combined with Fluoxetine.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Meclofenamic acid.]
[N05BA03, medazepam, The serum concentration of Medazepam can be increased when it is combined with Fluoxetine.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Fluoxetine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Dalteparin.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06DX01, memantine, The metabolism of Fluoxetine can be decreased when combined with Memantine.]
[N02AB02, meperidine, The risk or severity of serotonin syndrome can be increased when Meperidine is combined with Fluoxetine.]
[M03BX06, mephenesin, Mephenesin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Mephentermine is combined with Fluoxetine.]
[N03AB04, mephenytoin, The serum concentration of Mephenytoin can be increased when it is combined with Fluoxetine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02AX05, meptazinol, The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Fluoxetine.]
[N05AC03, mesoridazine, The serum concentration of Mesoridazine can be increased when it is combined with Fluoxetine.]
[N05AX13, paliperidone, The serum concentration of Paliperidone can be increased when it is combined with Fluoxetine.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Metformin.]
[A04AA04, dolasetron, The serum concentration of Dolasetron can be increased when it is combined with Fluoxetine.]
[H01CB03, lanreotide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Fluoxetine.]
[N06BA03, methamphetamine, The serum concentration of Metamfetamine can be increased when it is combined with Fluoxetine.]
[A03AB07, methantheline, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[H03BB02, methimazole, The metabolism of Fluoxetine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Pemetrexed can be decreased when combined with Fluoxetine.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02BG08, ziconotide, Ziconotide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Fluoxetine.]
[N05AA02, methotrimeprazine, The serum concentration of Methotrimeprazine can be increased when it is combined with Fluoxetine.]
[D05BA02, methoxsalen, The metabolism of Fluoxetine can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The serum concentration of Methoxyflurane can be increased when it is combined with Fluoxetine.]
[C03AA08, methyclothiazide, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Methyclothiazide.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Fluoxetine.]
[V04CG05, methylene blue, Fluoxetine may increase the serotonergic activities of Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Fluoxetine.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Fluoxetine.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Fluoxetine.]
[C03BA08, metolazone, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Metolazone.]
[C07AB02, metoprolol, The serum concentration of Metoprolol can be increased when it is combined with Fluoxetine.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Metronidazole.]
[C01BB02, mexiletine, The serum concentration of Mexiletine can be increased when it is combined with Fluoxetine.]
[N06AX03, mianserin, The serum concentration of Mianserin can be increased when it is combined with Fluoxetine.]
[S02AA13, miconazole, The metabolism of Fluoxetine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The serum concentration of Aminophenazone can be increased when it is combined with Fluoxetine.]
[B01AB07, parnaparin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Fluoxetine.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Tinzaparin.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Fluoxetine.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Fluoxetine.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06BA12, lisdexamfetamine, The serum concentration of Lisdexamfetamine can be increased when it is combined with Fluoxetine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Fluoxetine.]
[N02AA01, morphine, The risk or severity of serotonin syndrome can be increased when Morphine is combined with Fluoxetine.]
[A04AA05, palonosetron, The serum concentration of Palonosetron can be increased when it is combined with Fluoxetine.]
[L04AB05, certolizumab pegol, The metabolism of Fluoxetine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Fluoxetine.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Fluoxetine.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Fluoxetine can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The serum concentration of Amoxapine can be increased when it is combined with Fluoxetine.]
[N03AB05, fosphenytoin, The risk or severity of Anticonvulsant Toxicity can be increased when Fluoxetine is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The serum concentration of Nadolol can be increased when it is combined with Fluoxetine.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Ropinirole.]
[J01CF06, nafcillin, The metabolism of Fluoxetine can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02AF02, nalbuphine, The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Fluoxetine.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Fluoxetine.]
[L04AC03, anakinra, The metabolism of Fluoxetine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The serum concentration of Amphetamine can be increased when it is combined with Fluoxetine.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Naproxen.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Troglitazone.]
[N06AX21, duloxetine, The serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Fluoxetine.]
[L02BG04, letrozole, The metabolism of Fluoxetine can be decreased when combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Fluoxetine.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Repaglinide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Levosimendan.]
[B01AC17, tirofiban, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Tirofiban.]
[S01EB06, neostigmine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, The serum concentration of Iloperidone can be increased when it is combined with Fluoxetine.]
[N06AX23, desvenlafaxine, The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Fluoxetine.]
[C09CA07, telmisartan, The metabolism of Fluoxetine can be decreased when combined with Telmisartan.]
[C10AD02, niacin, The metabolism of Fluoxetine can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of serotonin syndrome can be increased when Nialamide is combined with Fluoxetine.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nicardipine.]
[C04AE02, nicergoline, The serum concentration of Nicergoline can be increased when it is combined with Fluoxetine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Fluoxetine.]
[N07BA01, nicotine, The metabolism of Fluoxetine can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The serum concentration of Nifedipine can be increased when it is combined with Fluoxetine.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nimodipine.]
[N05CD02, nitrazepam, The serum concentration of Nitrazepam can be increased when it is combined with Fluoxetine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nitrendipine.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N04BC05, pramipexole, Fluoxetine may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Fluoxetine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Bosentan can be decreased when combined with Fluoxetine.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Fluoxetine.]
[R05DA07, noscapine, The metabolism of Fluoxetine can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Eptifibatide.]
[L03AB07, interferon beta-1a, The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1a.]
[B01AB08, reviparin, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Reviparin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Fluoxetine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Fluoxetine.]
[N06AA05, opipramol, The serum concentration of Opipramol can be increased when it is combined with Fluoxetine.]
[N02AA02, opium, The serum concentration of Opium can be increased when it is combined with Fluoxetine.]
[B01AD07, reteplase, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Ancrod.]
[G04CA02, tamsulosin, The serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine.]
[P02BA02, oxamniquine, The metabolism of Fluoxetine can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Fluoxetine can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The serum concentration of Oxazepam can be increased when it is combined with Fluoxetine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The serum concentration of Oxprenolol can be increased when it is combined with Fluoxetine.]
[N02AA05, oxycodone, The serum concentration of Oxycodone can be increased when it is combined with Fluoxetine.]
[N02AA11, oxymorphone, The serum concentration of Oxymorphone can be increased when it is combined with Fluoxetine.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxytocin.]
[N05AH05, asenapine, The risk or severity of serotonin syndrome can be increased when Asenapine is combined with Fluoxetine.]
[B01AB09, danaparoid, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M03AC01, pancuronium, Pancuronium may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Papaverine.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C02KC01, pargyline, The risk or severity of serotonin syndrome can be increased when Pargyline is combined with Fluoxetine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Pefloxacin.]
[G04BD11, fesoterodine, The serum concentration of Fesoterodine can be increased when it is combined with Fluoxetine.]
[C07AA23, penbutolol, The serum concentration of Penbutolol can be increased when it is combined with Fluoxetine.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02AD01, pentazocine, The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Fluoxetine.]
[N05CA01, pentobarbital, Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C04AD03, pentoxifylline, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Pentoxifylline.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N04BC02, pergolide, The risk or severity of serotonin syndrome can be increased when Pergolide is combined with Fluoxetine.]
[C08EX02, perhexiline, The serum concentration of Perhexiline can be increased when it is combined with Fluoxetine.]
[N05AB03, perphenazine, The serum concentration of Perphenazine can be increased when it is combined with Fluoxetine.]
[N02BE03, phenacetin, The serum concentration of Phenacetin can be increased when it is combined with Fluoxetine.]
[N02AD02, phenazocine, The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Fluoxetine.]
[N06AF03, phenelzine, The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Phenelzine.]
[A10BA01, phenformin, The serum concentration of Phenformin can be increased when it is combined with Fluoxetine.]
[B01AA02, phenindione, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Pheniramine.]
[N03AA02, phenobarbital, Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Fluoxetine.]
[N01AH04, phenoperidine, The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Fluoxetine.]
[B01AA04, phenprocoumon, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Fluoxetine.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Fluoxetine can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Fluoxetine.]
[N03AB02, phenytoin, The risk or severity of Anticonvulsant Toxicity can be increased when Fluoxetine is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Fluoxetine can be increased when combined with Golimumab.]
[S01AE08, besifloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Besifloxacin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Physostigmine.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Fluoxetine.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Mibefradil.]
[N05AG02, pimozide, Fluoxetine may increase the QTc-prolonging activities of Pimozide.]
[C07AA03, pindolol, The serum concentration of Pindolol can be increased when it is combined with Fluoxetine.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Saquinavir.]
[P02CB01, piperazine, The serum concentration of Piperazine can be increased when it is combined with Fluoxetine.]
[N05AC04, pipothiazine, The serum concentration of Pipotiazine can be increased when it is combined with Fluoxetine.]
[A02BX03, pirenzepine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Fluoxetine.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of serotonin syndrome can be increased when Pizotifen is combined with Fluoxetine.]
[J05AG02, delavirdine, The serum concentration of Delavirdine can be increased when it is combined with Fluoxetine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Fluoxetine.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[B01AC13, abciximab, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Alteplase.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Rosiglitazone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fluoxetine.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L04AC08, canakinumab, The metabolism of Fluoxetine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Ritonavir can be increased when it is combined with Fluoxetine.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Saxagliptin.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Fluoxetine.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Fluoxetine.]
[C07AB01, practolol, The serum concentration of Practolol can be increased when it is combined with Fluoxetine.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Prajmaline.]
[N05BA11, prazepam, The serum concentration of Prazepam can be increased when it is combined with Fluoxetine.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Fluoxetine.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Prenylamine.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Primaquine.]
[N03AA03, primidone, Primidone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M04AB01, probenecid, The metabolism of Fluoxetine can be decreased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Probucol.]
[C01BA02, procainamide, The serum concentration of Procainamide can be increased when it is combined with Fluoxetine.]
[S01HA05, procaine, The risk or severity of serotonin syndrome can be increased when Procaine is combined with Fluoxetine.]
[L01XB01, procarbazine, The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Fluoxetine.]
[C10AB05, fenofibrate, The metabolism of Fluoxetine can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The serum concentration of Prochlorperazine can be increased when it is combined with Fluoxetine.]
[N04AA04, procyclidine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The serum concentration of Progesterone can be increased when it is combined with Fluoxetine.]
[N05AA03, promazine, The serum concentration of Promazine can be increased when it is combined with Fluoxetine.]
[R06AD02, promethazine, The serum concentration of Promethazine can be increased when it is combined with Fluoxetine.]
[C01BC03, propafenone, The serum concentration of Propafenone can be increased when it is combined with Fluoxetine.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[A03AB05, propantheline, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CM06, propiomazine, Propiomazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Romidepsin.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N02AC04, propoxyphene, The serum concentration of Dextropropoxyphene can be increased when it is combined with Fluoxetine.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Fluoxetine.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fluoxetine.]
[N02CC04, rizatriptan, The risk or severity of serotonin syndrome can be increased when Rizatriptan is combined with Fluoxetine.]
[B01AC09, epoprostenol, The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Fluoxetine.]
[N06AA11, protriptyline, The serum concentration of Protriptyline can be increased when it is combined with Fluoxetine.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Fluoxetine.]
[N05AX12, aripiprazole, The serum concentration of Aripiprazole can be increased when it is combined with Fluoxetine.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Fluoxetine is combined with Dalfampridine.]
[S01EB03, ecothiopate, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Echothiophate.]
[A03AB15, diphemanil, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Quinine can be increased when it is combined with Fluoxetine.]
[A02BA02, ranitidine, The metabolism of Fluoxetine can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J04AB02, rifampin, The metabolism of Fluoxetine can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Salicylic acid.]
[S01FA02, scopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Fluoxetine.]
[N04BD01, selegiline, The risk or severity of serotonin syndrome can be increased when Selegiline is combined with Fluoxetine.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Fluoxetine.]
[C07AA07, sotalol, The serum concentration of Sotalol can be increased when it is combined with Fluoxetine.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Fluoxetine.]
[C01DA14, isosorbide mononitrate, Fluoxetine may increase the vasodilatory activities of Isosorbide mononitrate.]
[H02CA04, levoketoconazole, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Levoketoconazole.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Tiaprofenic acid.]
[R03BB01, ipratropium bromide, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AF04, tranylcypromine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AF01, isocarboxazid, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AF03, phenelzine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N04BD01, selegiline, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
